Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Pfizer defeats race-bias lawsuit over minority fellowship program

Published 12/16/2022, 08:57 PM
Updated 12/16/2022, 11:00 PM
© Reuters.

By Nate Raymond

(Reuters) -A federal judge on Friday tossed a lawsuit by a group of medical professionals alleging a fellowship program established by Pfizer Inc (NYSE:PFE) to improve diversity within its higher ranks discriminates against white and Asian-American applicants.

Do No Harm, a group opposed to what it calls "radical, divisive, and discriminatory ideologies" in healthcare, alleged the drugmaker's Breakthrough Fellowship Program was discriminatory because only Blacks, Latinos and Native Americans could apply.

But U.S. District Judge Jennifer Rochon in Manhattan ruled the Virginia-based non-profit failed to show it had legal standing to sue Pfizer and seek an injunction as it would not identify by name any members of its group who could not apply to the program due to their race.

She said instead that it submitted "perfunctory" declarations from two anonymous white and Asian-American students at unnamed Ivy League universities "with little to no details about their career and educational goals, employment history, or interests."

She said even if the two members were identified, Do No Harm had failed to establish they were qualified to apply to the fellowship program, which aims to increase the pipeline of Black, Latino and Native American leaders at the drugmaker.

Rochon, an appointee of Democratic President Joe Biden, said Do No Harm, regardless, lacked standing to pursue the federal claims it asserted under several federal civil rights and anti-discrimination laws.

Pfizer in a statement welcomed the ruling, saying it was "proud of its commitment to diversity, equity, and inclusion." A lawyer for Do No Harm did not respond to requests for comment.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Pfizer launched the fellowship in 2021. Fellows receive two years of full-time jobs, fully funded master's degrees, and employment at New York-based Pfizer after completing the program. It aims to enroll 100 fellows by 2025.

The lawsuit was filed in September, a month before the U.S. Supreme Court heard arguments in a pair of cases against Harvard University and the University of North Carolina that could determine the future of affirmative action in higher education.

The Supreme Court, which has 6-3 conservative majority, appeared receptive to arguments by challengers to the universities' race-conscious admissions policies.

Do No Harm was launched in April, saying it wants to "stop this infiltration of politics in the healthcare system and particularly into medical education before it impacts quality and access to care."

Latest comments

Another pathetic Dem supporting racism and racial discrimination.
Probably. However the suit was tossed more on a technicality of "standing." Known Pfizer employees or employment candidates would have been better plaintiffs.
Keep going! Meritocracy will prevail and usa will be sacked as Rome
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.